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A B S T R A C T
Background: While ‘plaque rupture’ is the paradigm of type [40_TD$DIFF]1 myocardial infarction (T1MI), T2MI is
myocardial necrosis secondary to oxygen supply-demand mismatch. Being a heterogeneous and rather
newly deﬁned group, data are lacking about T2MI.
Methods: A retrospective review of medical records of patients diagnosed with T2MI in the Rabin
Cardiology Center, Israel between the years 2007 [41_TD$DIFF]and 2012 was performed. Following a descriptive
analysis, we used multivariate time dependent models to estimate the association of T2MI with
the risk for 30-day, 1-year, and 5-year all-cause-mortality and major adverse cardiovascular
events (MACE), and compared it to a T1MI group matched for age, gender and electrocardiographic
changes.
Results: The study included 107 T2MI (and 107 T1MI) patients. Sepsis, anemia, and atrial ﬁbrillation
were themost common etiologies. Triple anti-thrombotic therapy was given to 22% of T2MI patients (vs.
82% of T1MI patients, p < 0.001). Twenty[42_TD$DIFF]-ﬁve percent were managed using urgent percutaneous
coronary intervention. Angiography unmasked acute plaque rupture in 29% of T2MI patients group.
Compared to T1MI, T2MI was associated with higher all-cause-mortality rate: adjusted-hazard-ratio
7.14 [43_TD$DIFF](1.31–38.9) at 30 days, 3.42 [44_TD$DIFF](1.51–7.75) at 1 year, and 2.08 [45_TD$DIFF](1.14–3.81) at 5 years follow-up. MACE
risk was consistent between T2 and T1MI patients.
Conclusions: The most common T2MI triggers are sepsis, anemia, and atrial ﬁbrillation. Compared to a
T1MI population, T2MI is associated with higher short- and long-term mortality rates but equal
cardiovascular mortality and MACE risk. As many as 30% may harbor plaque rupture and in fact have
T1MI.
 2015 Published by Elsevier Ltd on behalf of Japanese College of Cardiology.Introduction
Type 2 myocardial infarction (T2MI) is deﬁned as cardiomyo-
cyte necrosis caused by conditions other than atherosclerotic
coronary artery disease (CAD) and secondary to decrease in oxygen
supply (e.g. hypoxemia, anemia, hypotension, and endothelial
dysfunction) and/or increased demand (e.g. tachycardia, arrhyth-
mia, and sepsis) [1]. Although believed to constitute as many as
25% of all MIs in hospitalized patients [2] and strongly associated* Corresponding author [36_TD$DIFF]at: Department of Cardiology [37_TD$DIFF], Beilinson Hospital – Rabin
Medical Center, Jabotinski St. 39, Petah-Tikva [38_TD$DIFF] 9100, Israel. Tel.: +972 03 9377107;
fax: +972 [39_TD$DIFF]09249850.
E-mail address: ran.kornowski@gmail.com (R. Kornowski).
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0914-5087/ 2015 Published by Elsevier Ltd on behalf of Japanese College of Cardiolowith a high mortality rate [3,4], as a heterogeneous and relatively
newly deﬁned group, little is known about T2MI patients. Since
2007, when the diagnosis was ﬁrst introduced by the Universal
deﬁnition, it raised awareness, documentation and quality review
programs, and holds promise to improve outcome for these
patients in the future [5]. While plaque rupture is the designation
paradigm of T1MI, it is often difﬁcult to exclude atheroembolic
acute coronary events in patients thought to suffer T2MI. Whether
and when to attempt revascularization among patients hospital-
ized with severe sepsis and ischemic electrocardiographic (ECG)
changes with new elevated troponin level is based on clinical
judgment. The magnitude of beneﬁt, if any, of anti-platelets and
anti-coagulant medications in these patients has yet to be deﬁned.
Apart from treating the underlying condition, there are neither
guidelines nor a consensus on the optimal management of T2MIgy.
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to predict which patients suffer pure secondary MI and which
harbor acute coronary events. The objective of our study was to
characterize T2MI patients concerning baseline characteristics,
clinical presentation, management, and outcome, with a compari-
son to a T1MI patient groupmatched for age (2 years), sex, and ST-
elevation (STE).
Methods
In our cardiology department at Rabin Medical Center in Israel,
we used electronic medical, pharmacy, and laboratory record
systems to review records of patients admitted and diagnosed
with T2MI between the years 2007 [46_TD$DIFF]and 2012. We validated the
diagnosis and included only patients who fulﬁlled both of the
following criteria:[47_TD$DIFF]1. Detection of a rise and/or fall of cardiac troponin T (cTnT)with at
least one value above the 99th percentile upper reference limit
(URL) and with at least one of the following:
A. Symptoms of ischemia.
B. New or presumed new signiﬁcant ST–T changes, left bundle
branch block (LBBB [48_TD$DIFF]), or pathologic Q waves.
C. Imaging evidence of new loss of viable myocardium or new
regional wall motion abnormality (RWMA).[49_TD$DIFF]cTnT assay was performed on Roche Elecsys 2010 (Basel,
Switzerland) and Roche Cobas e 411 instruments, using the
electrochemiluminescence immunoassay. Between 2007 [50_TD$DIFF]and
2010 we used cTnT 4th Gen. The limit of quantiﬁcation
(functional sensitivity) was 30 ng/L, and the URL (99th
percentile) was 10 ng/L. From 2010 until the end of the study
we used cTnT hs (high sensitive). The limit of quantiﬁcation
(functional sensitivity) was 13 ng/L, and the URL (99th
percentile) was 14 ng/L.[51_TD$DIFF]2. At least one of the following conditions considered to trigger
imbalance between myocardial O2 supply [52_TD$DIFF]-demand (supported,
partially, on data from the literature [2,5,7–9]):
A. Sepsis-systemic inﬂammatory response syndrome (SIRS)
which consists of  [53_TD$DIFF]two of the following: fever > 38 [54_TD$DIFF]8C,
tachypnea > 24 breaths/min, tachycardia > 100 beats/min,
leukocytes> 12 K/mL, in the context of clinically suspected/
documented infection.
B. Shock [55_TD$DIFF]– deﬁned as systolic blood pressure (BP) < 90 mmHg
and/or diastolic BP < 60 mmHg together with evidence of
systemic hypo-perfusion (lactatemia).
C. Anemia (severe) [56_TD$DIFF]– deﬁned as a fall in [57_TD$DIFF]2 g/dL hemoglobin (Hb)
and/or Hb< 10 g[58_TD$DIFF]/dL and/or a need to use blood products.
D. Active bleeding [56_TD$DIFF]– visualization of blood in stool, vomit,
gastric aspirate, or endoscopy.
E. Tachyarrhythmia [56_TD$DIFF]– ventricular rate > 120/min excluding
sinus tachycardia.
F. Bradyarrhythmia [56_TD$DIFF]– requirement of medical treatment or
cardiac pacing.
G. Respiratory failure [56_TD$DIFF]– requirement of mechanical ventilation
(invasive or non-invasive).
H. Hypertensive crisis [59_TD$DIFF]– systolic BP > 180 mmHg and concomi-
tant progressive retinopathy and/or encephalopathy.[60_TD$DIFF]We then used a matching algorithm which sequentially
searched a 4524 T1MI patient cohort (all T1MI patients admitted
to our department between years 2007 [61_TD$DIFF]and 2012), matching for
sex, ST segment elevation, and searching for the closest match
for age (year [62_TD$DIFF]2). Each selected pair was then removed from the
search algorithm until a 1:1 matching process was completed. T1MIdiagnosis was validated according to the ﬁrst of the two above-
mentioned criteria.
The study protocol was approved by the Helsinki Committee of
the Rabin Medical Center.
[63_TD$DIFF] eﬁnition of covariates[64_TD$DIFF]:
After descriptive analysis of baseline characteristics and clinical
presentation, we usedmultivariate time dependent Cox regression
models to estimate the association of T2MIwith the risk for 30-day[65_TD$DIFF],
1-year, and 5-year major adverse cardiovascular events (MACE)
[cardiovascular (CV)-death, urgent percutaneous coronary inter-
vention (PCI), stroke, and re-MI] and all-cause-mortality. CV
mortality was deﬁned as death due to acute coronary and [66_TD$DIFF]/or aortic
syndrome, cardiac arrhythmias, congestive heart failure (CHF),
stroke, pulmonary emboli, or during cardiac interventions. All
other deaths were considered non-CV. The cause of death was
adjudicated blindly with respect to MI type. Re-MI was deﬁned as
recurrence of chest pain or ECG changes and new cTnT elevation.
Urgent PCI was deﬁned as PCI for re-MI or unstable angina during
follow-up. CHF was deﬁned as left ventricular ejection fraction
(LVEF) < 40% and/or a history of CHF. Patients without history of
CHF but with missing LVEF data were excluded from the CHF
analysis. ECG changes were considered ischemic when there was
evidence of new ST segment deviation, T wave inversion, LBBB, or
pathologic Qwave.We conducted angiographic characterization of
coronary lesions morphology using features of complexity
previously described by Ambrose et al [67_TD$DIFF]. [10–13]. Lesions were
considered ‘complex’ if they exhibited either: [68_TD$DIFF](A) An intraluminal
ﬁlling defect consistent with thrombus, deﬁned as abrupt vessel
cutoff with persistence of contrast or ﬁlling defect observed in
multiple views; [69_TD$DIFF](B) Plaque ulceration, deﬁned by the presence of
contrast beyond, but contiguous to the vessel lumen; or [70_TD$DIFF](C) Two or
more of the following: (a) ﬁssuring, deﬁned by intra-plaque dye
penetration not meeting deﬁnition of ulceration; (b) plaque
irregularity, deﬁned by irregular margins or overhanging edges;
or (c) intraluminal haziness. Lesions not meeting these criteria
were considered to be ‘noncomplex.’ The angiographic analysis
and interpretation [71_TD$DIFF]were carried out by an experienced cardiologist
blinded to the original angiographic interpretations and to the MI
type as well as to the clinical outcome. We only analyzed lesions
that were associated with at least 50% stenosis.
[72_TD$DIFF]Statistical methods
Categorical data were reported as numbers (percentages), [73_TD$DIFF]and
continuous data were reported as means [standard deviations
(SD)] and medians [interquartile ranges (IQRs)]. Comparisons
between groups for categorical data were made with the Chi-square
or Fisher[74_TD$DIFF]’s exact tests, whereas continuous data were compared using
[75_TD$DIFF]two-sample t-tests or Mann–Whitney test. Univariate Cox propor-
tional hazards models were used to assess the impact of MI type and
other variables on all-cause-mortality, CV-mortality, and MACE. MI
type and variables with p < 0.2 in the univariate analysis were
included in the multivariate analysis. Cox proportional hazards
models were used to assess the impact of MI type on all-cause-
mortality, CV-mortality, and MACE, while controlling for confoun-
ders. As the groups werematched for age [76_TD$DIFF](2 years), sex, and STE, the
only other covariates included in the multivariate analysis, speciﬁ-
cally: ischemic heart disease (IHD), diabetes mellitus, chronic kidney
injury (CKI), LVEF at presentation, pulmonary congestion, Hb level (g [58_TD$DIFF]/
dL), creatinine (Cr) level (mg/dL), and cTnT level (ng/mL). Analyses
were repeated separately in patients with or without sepsis, with or
without anemia, and with or without arrhythmia. These stratiﬁed
analyses allowed us to explore the associations between T2MI and the
primary outcomes differences according to T2MI major subgroups.
Kaplan[77_TD$DIFF]–Meier curves were constructed to estimate the survival
function of all-cause-mortality, CV-mortality, and MACE within T2MI
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cause[78_TD$DIFF]-mortality, and end of follow[79_TD$DIFF]-up after indexMI, whichever came
ﬁrst. For all data analyses we used IBM-SPSS Statistics for Windows,
version 19.0 [80_TD$DIFF](IBM Corp., Armonk, NY, USA) and R version 3.0.2. All p-
values were two-sided, and a p-value of [81_TD$DIFF]<0.05 was considered
statistically signiﬁcant.
[82_TD$DIFF]Results
Between the years 2007 [83_TD$DIFF]and 2012 there were 4283 patients
admitted with MI to our Cardiology Department. Among those, we
identiﬁed 148 patients admittedwith T2MI after review ofmedical
records, 41 patients were excluded from the study: 15 had
insufﬁcient data on serum cTnT level (rise and/or fall were not
demonstrated), 12 had no trigger as deﬁned by the inclusion
criteria, 8 had features of takotsubo cardiomyopathy, 2 were
diagnosedwith aortic dissection, 2 had type 4a (periprocedural)MI
and 2 4b (stent thrombosis) MI. Therefore, the ﬁnal analysis
included 107 veriﬁed T2MI and 107 properly matched T1MI
patients. Patients’ baseline characteristics and clinical presentation
(including the matched parameters) are summarized in Table 1.
The mean age of T2MI cohort was 74 years, with 35% female
patients. About half of the patient cohort had diabetes mellitus,
54 patients (72% of patients with available pre-MI echo data) had
good baseline LV function. STEMI on admission was detected in 11
(10.3%) patients, and ischemic ECG changes were absent in 25
(33.1%) patients. While chest pain/discomfort was signiﬁcantly
less frequent among T2MI patients compared to T1MI patientsTable 1
Baseline characteristic and clinical presentation, [6_TD$DIFF]n (%).
Type I MI Type II MI p-[7_TD$DIFF]Value
Baseline characteristic
[8_TD$DIFF]Age (years) 72 (12.5) 74 (10.4) 0.134
Female 38 (35.5) 38 (35.5) 1
Diabetes mellitus 54 (50.5) 54 (50.5) 1
Baseline LV function [9_TD$DIFF](%) 0.8555
Good LV function 37 (68.5) 54 (72)
[10_TD$DIFF]Mild LVD 6 (11.1) 6 (8)
[11_TD$DIFF]Moderate LVD 6 (11.1) 10 (13.3)
[12_TD$DIFF]Severe LVD 5 (9.3) 5 (6.7)
Ischemic heart disease 50 (46.7) 68 (63.6) 0.013
Past angioplasty 38 (35.8) 49 (46.2) 0.125
Hypertension 82 (76.6) 87 (81.3) 0.402
Hypercholesterolemia 69 (64.5) 82 (76.6) 0.051
Chronic kidney injury 17 (15.9) 29 (27.1) [13_TD$DIFF]0.046
Smoking 41 (38.3) 44 (41.9) 0.594
Dementia 4 (3.7) 4 (3.7) 1
Malignancy 4 (3.7) 4 (3.7) 1
[14_TD$DIFF]Presentation
ST segment elevation 11 (10.3) 11 (10.3) 1
In hospital 4 (3.7) 51 (47.7) [15_TD$DIFF]<0.001
ECG ischemic changes 75 (70.1) 71 (66.4) 0.557
Chest pain 103 (96.3) 65 (61.3) [15_TD$DIFF]<0.001
Dyspnea 38 (35.5) 78 (72.9) [15_TD$DIFF]<0.001
Pulmonary congestion 18 (16.8) 37 (34.6) 0.003
LV [16_TD$DIFF]function at
presentation
0.448
Good LV function 42 (40.8) 40 (40.4)
[10_TD$DIFF]Mild LVD 23 (22.3) 19 (19.2)
[11_TD$DIFF]Moderate LVD 28 (27.2) 23 (23.2)
[12_TD$DIFF]Severe LVD 10 (9.7) 17 (17.2)
RWMA at [17_TD$DIFF]presentation 80 (77.7) 74 (74) 0.541
Troponin T [ng/mL] 1.4 (2.3) 1 (1.4) 0.128
Creatine kinase [U/L] 584.9 (858.1) 602.6 (242.5) 0.944
Creatinine [mg/dL] 1 (0.4) 1.6 (1.5) [18_TD$DIFF]<0.001
Hemoglobin [g/dL] 13.3 (2.1) 10.2 (2.2) [19_TD$DIFF]<0.001
Categorical data reported as number and percentage (%). Continuous data
reported as means (standard deviations). MI, myocardical infarction; LV, left
ventricle; LVD, LV dysfunction; RWMA, regional wall motion abnormality.
[1_TD$DIFF]Signiﬁcance of bold values is p< 0.05.(61.3% vs. 96.3%, p < [84_TD$DIFF]0.001), pulmonary congestion was signiﬁ-
cantly more prevalent (34.6% vs. 16.8%, p = 0.003). There was no
difference between the cohorts in terms of LV function or RWMA.
Compared with T1MI patients, T2MI mean serum creatinine
level was higher (1.6 mg/dL vs. 1.0 mg/dL, p < 0.001), and mean
serum Hb was lower (10.2 g [85_TD$DIFF]/dL vs. 13.3 g/dL, p < 0.001). The mean
serum cTnT level was 1.0 (1.4) ng/dL and 1.4 (2.3) ng/dL in T2 and
T1 patients, respectively. This difference did not reach a statistically
signiﬁcant threshold (Table 1).
A quarter of the cases developed post-surgically, the majority
following vascular surgery. The mean surgery-to-MI time was
2.1 days (2.3 SD). As sepsis was the most prevalent trigger, fever
was present in 36.4%, and positive blood cultures were obtained in
5.6%. More than a third of the patients had an arrhythmic trigger [86_TD$DIFF]– all
were tachyarrhythmia, most commonly rapid atrial ﬁbrillation (AF).
In the majority of patients, more than one trigger was present.
The majority of T2 patients were treated with aspirin, less than
half were treated with dual anti-platelet therapy, and only 38%
were treated with an anti-coagulant. Triple anti-thrombotic
therapy (aspirin plus anti-coagulant plus ADP-antagonist medica-
tion) was given to 22% and 82% of T2 and T1 patients, respectively
(p < 0.001). Excluding statins, all other drugs commonly used for
the intensive medical management of acute coronary syndrome
were used signiﬁcantly less in T2 patients. Repeating data analysis
after excluding patients with anemia or active bleeding did not
change these differences in the medical management strategy.
Only 29 (27.1%) patients had beenmanaged invasively with urgent
coronary angiography. Of those, less than half (48.4%) underwent
mechanical coronary reperfusion (compared with 79.1% of T1MI
patients). Of note, 30.8% of T2MI patients suitable for coronary
reperfusion were transferred to coronary artery bypass graft
surgery as compared with 7.3% in the T1 group. Angiographic
analysis of the study group revealed acute plaque rupture
characteristics in 29% of the coronary lesions (Fig. 1).
Finally, with multivariate analysis, we estimated the associa-
tion between MI types and the risk for 30-day, [87_TD$DIFF]1-year, and 5-year
MACE and all-cause-mortality. At all time intervals, T2MI was
associated with a signiﬁcant increase in all-cause[78_TD$DIFF]-mortality. By
contrast, MACE risk was consistent between T2MI and T1MI
patients. Results are summarized in Table 2. The Kaplan–Meier
curves for all-cause-mortality and MACE for T2MI vs. T1MI
matched patients are shown in Fig[1_TD$DIFF]. 2.
The 11 patientswho presentedwith STE-T2MI did not show any
difference in clinical characteristics compare with the other
96 T2MI patients. This is probably because the study is
underpowered to answer this question reliably. Moreover, only
[88_TD$DIFF]three STE-T2MI patients had plaque rupture features on coronary
angiography, which is the same frequency observed in NSTE-T2MI.
We also compared, using multivariate subgroups analysis,
outcomes for the invasive (urgent PCI, 29 patients) vs. conservative
(no PCI, 78 patients) T2MI patients management: the adjusted-
hazard-ratio (HR) and 95% conﬁdence-interval (CI) for all-cause-
mortality was 0.57 [89_TD$DIFF](0.16–1.99) at 30 days (p = 0.378) and 0.59
[90_TD$DIFF](0.26–1.35) at 1 year (p = 0.208). The adjusted HR for MACE was
1.18 [91_TD$DIFF](0.36–3.83) at 30 days (p = 0.784) and 0.61 [92_TD$DIFF](0.23–1.62) at
1 year (p = 0.318).
Discussion
It is a clinical challenge to determine whether myocardial
necrosis is secondary to supply-demand oxygen mismatch
[14]. Troponin is a sub-optimal prognostic marker in critically ill
patients [15–17], and sepsis, pulmonary disease, renal failure, and
stroke may cause elevated cTn levels [18–21], reﬂecting non-
ischemic cTn elevation. Therefore, it is essential to distinguish
between the ischemic nature of myocardial injury by clinical signs
[(Fig._1)TD$FIG]
Fig [1_TD$DIFF]. 1. Examples from coronary angiography of two type 2 myocardial infarction
study patients showing ‘‘non-complex’’ (a) and ‘‘plaque rupture’’ lesions
characteristics (b).
U. Landes et al. / Journal of Cardiology 67 (2016) 51–5654and symptoms, ECG changes and cardiac imaging [1], and then to
distinguish the cause (T1MI vs. T2MI). We restricted our study to
patients with anginal symptoms, ischemic ECG changes, or RWMA,
to include only patients with ischemic nature troponin dynamics.
Furthermore, as there are no internationally accepted criteria,
we had meticulously pre-deﬁned our T2 trigger standards, based,
to some extent, on data from the literature. Consequently, we
describe herein 107 T2MI and 107 T1MI patients admitted to our
center during a 6-year period. The groups were matched accordingTable 2
Risk for all-cause-mortality and MACE, T2MI vs. matched T1MI.
Outcome HRAdja (95% CI) p-Value
All-cause-mortality
[22_TD$DIFF]30 days 7.14 (1.31–38.9) 0.023
1 year 3.42 (1.51–7.75) [23_TD$DIFF]0.003
5 years 2.08 [24_TD$DIFF](1.14–3.81) 0.017
MACE
30 days 1.07 [25_TD$DIFF](0.49–2.31) 0.871
1 year 1.05 (0.51–2.17) 0.895
5 years 1.02 [26_TD$DIFF](0.59–1.76) 0.950
MACE, major adverse cardiovascular events; T2MI, type 2 myocardial infarc-
tion; T1MI, type 1 myocardial infarction; HRAdj, adjusted [27_TD$DIFF]-hazard-ratio; CI,
conﬁdence interval.
[28_TD$DIFF]aAdjusted for: ischemic heart disease, chronic kidney injury, left-ventricular
ejection fraction at presentation, pulmonary congestion, hemoglobin level,
creatinine level [mg/dL] and cardiac troponin T level (ng/mL).
[2_TD$DIFF]Signiﬁcance of bold values is p<0.05.to three key baseline characteristics to empower signiﬁcance toMI
type, rather than to the effect of the aforementioned important
variables. During the 6-year study period, T2MI was diagnosed
in 2.2% of MI patients admitted to our center. In line with our
results, Morrow et al. and Bonaca et al. classiﬁed T2MI in 3.5% ofMI
patients [22], Melberg et al. and Szyman´ski et al. in 1.6% and 2%,
[93_TD$DIFF]respectively [23,24]. Conversely, Javed et al. reported T2MI in
29.6% of MI patients [25], and Saaby et al. in 26% [2]. There are only
few studies on T2MI, and inclusion criteria between studies vary.
The lack of consistency in patients’ selection criteria is the likely
cause for this heterogeneity in incidence. STE-T2MI is reported to
represent [94_TD$DIFF]0–23% of T2MI in different studies [2–4]. In our study,
10% of T2MI patients were presented with STE. While the mean
cTnT level was lower in T2MI compared with T1MI patients,
possibly since the study was underpowered, this difference did not
reach the statistically signiﬁcant threshold, as it did in other
studies [2]. An intriguing ﬁnding was that while both groups
presented with similar LV function level, dyspnea and pulmonary
congestion were signiﬁcantly more frequent in T2 patients. This
may be explained by a non-cardiogenic component in the T2MI
pulmonary congestion, as SIRS is more frequently present in these
patients. Apart from our study, only one study, to the best of our
knowledge [2], predeﬁned criteria for triggers to reﬂectmyocardial
O2 imbalance. As opposed to our study, septic patients were
excluded from the study, reasoning that cTnT elevation in sepsis
does not reﬂect overt myocardial ischemia. Despite the evidence
that myocardial necrosis in septic patients may reﬂect a non-
ischemic inﬂammatory reaction of the myocardium, as was shown
in some cardiac magnetic resonance imaging studies [21], we
argue that in the presence, and only in the presence of ischemic
clinical scenario (chest pain, ischemic ECG changes, or cardiac
imaging), referring troponin dynamics as ‘‘non-ischemic’’ is both
impractical and inappropriate. Moreover, as SIRS can cause
tachycardia (as tachycardia is one of the SIRS criteria), it may
elevate myocardial oxygen demand and cause demand-supply
imbalance. Also in SIRS, endothelial cells are precociously exposed
to signalingmolecules and physical stresses which lead to increase
in inducible nitric oxide synthase expression and a negative
feedback on endothelial nitric oxide synthase expression, with
subsequent deregulation of nitric oxide signaling. Endothelial
dysfunction is known to play amajor role in the pathophysiology of
organ dysfunction in sepsis [26].Wemaintain sepsis to be themost
common T2MI etiology.
There are neither guidelines nor consensus for managing T2MI
patients [1,8,9]. Yet these patients are frequently treated with
antithrombotic medications and or PCI, based solely on empirical
decision making [27]. To date, there has been no study conducted
to seek and verify the effectiveness of these treatments in T2MI. As
it is apparently caused by a non-thrombotic mechanism, it is
intuitive that such approaches will not be as effective as in T1MI.
Indeed, such treatments are contraindicated in many T2 patients
due to high risk for bleeding. We found that, even after excluding
anemic and bleeding patients, triple-antithrombotic therapy was
given to only 22% of T2MI patients, and that only 29 (27.1%) of
T2MI patients had been managed with urgent coronary angiogra-
phy. PCI was not associated with improved outcomes, albeit our
study is underpowered to address this question reliably. A
signiﬁcant CAD was demonstrated in 75% of T2MI patients as
opposed to 55% reported in the literature [2]. Aswe analyzed lesion
morphology, we diagnosed acute plaque rupture in 29% of the
patients. Recently, Hanson [95_TD$DIFF]et al. [10] described the angiographic
features of perioperative MI following non-cardiac surgery: 59%
had plaque rupture features and 41% had stable coronary features.
It is reasonable to assume that in speciﬁc T2MI patients, the
element of inﬂammation and hyper-coagulation cause acute
progression of pre-existing coronary lesions (T1MI), on top of
[(Fig._2)TD$FIG]
Fig [1_TD$DIFF]. 2. (a) Kaplan–Meier curves for [2_TD$DIFF]30-day all-cause-mortality: T2MI vs. T1MI patients. (b) Kaplan–Meier curves for [3_TD$DIFF] 0-day MACE: T2MI vs. T1MI patients. (c) Kaplan–Meier
curves for [4_TD$DIFF]5-year all-cause-mortality: T2MI vs. T1MI patients. (d) Kaplan–Meier curves for 5-year MACE: T2MI vs. T1MI patients. [5_TD$DIFF] 2MI, type 2 myocardial infarction; T1MI,
type 1 myocardial infarction; MACE, major adverse cardiovascular events.
U. Landes et al. / Journal of Cardiology 67 (2016) 51–56 55the oxygen mismatch myocardial damage (T2MI) [27]. Careful
clinical judgment and identiﬁcation of the more dominant
ischemic mechanism [96_TD$DIFF]are the key in determining a proper
treatment strategy.
Compared with the T1MI patients group, we found T2MI to be
associated with HR 7.14 (p = 0.023) for 30-day mortality, HR 3.42
(p = 0.003) for [97_TD$DIFF]1-year mortality, and HR 2.08 (p = 0.017) for 5-year
mortality. The highest mortality risk appeared during the ﬁrst
6 months after the index event, after which the slopes of the
mortality curves almost paralleled ( [98_TD$DIFF] ig. 2c). We found T2MI not to
constitute higher risk for CV-death or MACE compared to T1MI.
Similar ﬁndings were shown in a post [99_TD$DIFF]hoc analysis of the TRITON-
TIMI 38 Trial that reported increased but consistent CV-death
across T1 and T2MI patients [3].
[100_TD$DIFF]Limitations
Our study has the inherent limitations of a retrospective study.
The association between T2MI and mortality may still be over-
estimated due to unmeasured confounders, and our subgroup
analyses are limited by small sample size. Speciﬁcally, few
angiograms were done in the type 2 patients. Additionally, our
study may suffer a selection bias, since it is based on records fromcardiology department admissions, while at least half of T2MI
patients are admitted to non-cardiology departments [2]. In
cardiology wards, T2 [101_TD$DIFF]patients may be younger and suffer less
comorbidity than T2 [101_TD$DIFF]patients admitted to other wards. Nonethe-
less, the mean age and other baseline characteristics of T2MI
patients in our study are similar to those reported in other studies
[2,4,20,22,25].
Summary [102_TD$DIFF]and conclusions
T2MI is still an ambiguous diagnosis,most commonly caused by
sepsis, arrhythmia, and anemia. It is associated with higher
mortality and equal CV-mortality and MACE compared to T1MI.
While it is a clinical diagnosis, as many as [103_TD$DIFF]one third of the T2MI
patients have in fact angiographic diagnosis of T1MI, with plaque
rupture characteristics. Larger prospective studies are warranted,
with an adaption of universal consensus criteria.
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